GenoScreen develops advanced DNA analysis services and technologies for research and innovation in the life sciences. Thanks to constant investment in R&D and specialization in molecular microbiology, our evolution has been built in three stages:
Launch of genomic analytics services to meet the needs of academic research teams
Development of collaborative R&D with research laboratories
Development of proprietary solutions in molecular microbiology
A look back at the key moments in our history
2001
Creation of GenoScreen
RIO-certified platform
2004
Launch of an R&D activity
INPI Trophy
CIR accreditation
2006
First publication
First patent filed
2007
OTC patent filed Biomarker for Alzheimer's disease
Launch of MIRU typing service
for M. tuberculosis (tuberculosis)
2009
Export sales exceed 30%
Platform awarded "IBISA" label
Deloitte Technology Fast 50 Trophy
Joining the Oséo excellence community
2010
Release of the “Microsatellite Bank” offer
Launch of the “MEDIALZ” project (Alzheimer's disease)
2011
Patho-Ngen-Trace" project launched (FP VII)
INPI prize for innovation and creativity
2012
EQUIPEX validated sequencing platform
Optimization of metagenomics services
2013
Launch of industrial R&D partnerships
2014
Launch of the MIRU-VNTR kit
Launch of Metabiote® engineering
GCLP (Good Clinical Laboratory Practice) recognition for microbiota analysis
2015
ISO 9001 Certificates
2016
ISO 13485 Certificates
2018
DIAMA" project (Evaluation and validation
of the Deeplex® Myc-TB test in Africa and Europe)
2019
Launch of the Deeplex® Myc-TB kit
Participation in the “GenoSol” project (mapping of French soils)
“PEOPLE” project, funded by the EDCTP (European & Developing Countries Clinical Trials Partnership)
2020
Launch of the Brucella MLVA-16 offer
CE-IVD marking for Deeplex® Myc-TB
More than 70 publications with GenoScreen researchers listed as authors
2021
Launch of the “Seq&Treat” project under the guidance of FIND and WHO
2022
Launch of sequencing services
on the Oxford Nanopore platform
2023
Establishment of a partnership with Illumina
Launch of Deeplex® Myc-Lep and Deeplex® HelP
Launch of GenoBiome®
2024
The WHO validates and recommends tNGS technology,
developed from Deeplex® engineering kits
Export sales reach 50%
2025
Launch of Deeplex® TB XL
Over 80 publications with GenoScreen researchers listed as authors
Développement de qPCR
sur mesure
Design in silico, validation in vitro,
optimisation des conditions expérimentales
Optimisation et validation de
designs existants
Détermination des seuils LOD/LOQ,
tests sur matrices complexes
Aide au transfert et validation
sur vos équipements
Assistance pour l'intégration de la méthode
sur votre matériel
Évaluation complète
des performances analytiques
Détermination des seuils LOD/LOQ,
tests sur matrices complexes